Female gender (yrs), n (%)
|
20 (47.6%)
|
37 (50.7%)
|
0.75
|
Age (yrs), mean ± SD
|
66.6 ± 15.6
|
68.5 ± 15.1
|
0.54
|
ICU admission, n (%)
|
15 (35.7%)
|
24 (32.9%)
|
0.76
|
Previous hospitalization, n (%)
|
21 (50.0%)
|
37 (50.7%)
|
0.94
|
APACHE II score at study enrollment, mean ± SD
|
21.8 ± 7.2
|
21.9 ± 7.6
|
0.92
|
Mechanical ventilation, n (%)
|
39 (92.9%)
|
58 (79.5%)
|
0.06
|
Indwelling central venous catheter, n (%)
|
28 (66.7%)
|
40 (54.8%)
|
0.21
|
Surgery, n (%)
|
26 (61.9%)
|
39 (53.4%)
|
0.38
|
Chronic intermittent hemodialysis, n (%)
|
4 (9.5%)
|
10 (13.7%)
|
0.51
|
Antibiotic use for current hospitalization prior to study enrollment and during study period, n (%)
|
Carbapenems
|
35 (83.3%)
|
66 (90.4%)
|
0.26
|
Cephalosporins
|
20 (47.6%)
|
31 (42.5%)
|
0.59
|
Beta-lactam/beta-lactamase inhibitors
|
33 (78.6%)
|
52 (71.2%)
|
0.39
|
Fluoroquinolones
|
25 (59.5%)
|
33 (45.2%)
|
0.14
|
Vancomycin
|
23 (54.8%)
|
38 (52.1%)
|
0.78
|
Aminoglycosides
|
5 (11.9%)
|
2 (2.7%)
|
0.10
|
Antibiotic use for the current hospitalization after study enrollment, n (%)
|
Carbapenems
|
19 (45.2%)
|
34 (46.6%)
|
0.89
|
Cephalosporins
|
6 (14.3%)
|
4 (5.5%)
|
0.17
|
Beta-lactam/beta-lactamase inhibitors
|
25 (59.5%)
|
36 (49.3%)
|
0.29
|
Fluoroquinolones
|
19 (45.2%)
|
25 (34.2%)
|
0.24
|
Vancomycin
|
17 (40.5%)
|
27 (37.0%)
|
0.71
|
Aminoglycosides
|
4 (9.5%)
|
2 (2.7%)
|
0.19
|
Colistin use within 3 months prior to study enrollment, n (%)
|
9 (21.4%)
|
2 (2.7%)
|
0.002
|
Total amount of colistin (mg), median (range)
|
2800 (400–9350)
|
2000 (300–10,650)
|
0.03
|
Total duration of colistin use (days), median (range)
|
13 (2–55)
|
9 (1–32)
|
0.03
|
Total courses of colistin therapy, mean ± SD
|
1.3 ± 0.6
|
1.1 ± 0.34
|
0.02
|
Total courses of colistin therapy, range
|
1–3
|
1–3
| |
Patients who received more than 1 course of colistin therapy, n (%)
|
10 (23.8%)
|
6 (8.2%)
|
0.02
|
Length of hospital stay (days), median (range)
|
46.5 (12–246)
|
32 (6–192)
|
0.04
|
All-cause mortality at hospital discharge, n (%)
|
35 (47.9%)
|
19 (45.2%)
|
0.78
|